Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

• Jessica Davies ,

  * E-mail: Jessica.Davies@roche.com

  Affiliation F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom

  http://orcid.org/0000-0002-1098-2138

  ⨯
• Manali Patel,

  Affiliation Division of Oncology, Stanford University School of Medicine, Stanford, California, United States of America

  ⨯
• Cesare Gridelli,

  Affiliation Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy

  ⨯
• Filippo de Marinis,

  Affiliation Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy

  ⨯
• Daniel Waterkamp,

  Affiliation Diagnostics Information Solutions, F. Hoffmann-La Roche AG, Pleasanton, California, United States of America

  ⨯
• Margaret E. McCusker

  Affiliation Diagnostics Information Solutions, F. Hoffmann-La Roche AG, Pleasanton, California, United States of America

  ⨯